ITPR2

Across TCGA pan-cancer cohorts, ITPR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITPR2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ITPR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITPR2 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

OV, HNSC, and GBM are the cancer types where ITPR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Quartile	All	0.627	0.896	.042	8	view →
HNSC	DFS	Tertile	IV	0.656	0.929	.013	6	view →
GBM	DFS	Tertile	All	0.453	0.257	.025	4	view →
UCEC	OS	Quartile	All	1.000	0.872	.023	4	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →
PDAC	OS	Median	All	0.471	0.606	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITPR2–OV (DFS)

Open the OV breakdown →